Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2006-09-01 (19 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CHASSENEUIL-SUR-BONNIEURE (16260), Charente
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE BREVIERE : revenue, balance sheet and financial ratios
PHARMACIE BREVIERE is a French company
founded 19 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CHASSENEUIL-SUR-BONNIEURE (16260),
this company of category PME
shows in 2023 a revenue of 3.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BREVIERE (SIREN 491532826)
Indicator
2025
2024
2023
2022
2021
2020
Revenue
N/C
N/C
3 239 048 €
N/C
N/C
N/C
Net income
309 956 €
206 186 €
298 031 €
440 403 €
224 440 €
211 297 €
EBITDA
N/C
N/C
382 911 €
N/C
N/C
N/C
Net margin
N/C
N/C
9.2%
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE BREVIERE generates positive net income of 310 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2025: 211 k€ -> 310 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
309 956 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 127%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
126.615%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
41.17%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Debt ratio
6.179
5.053
3.722
65.077
73.947
126.615
Financial autonomy
89.687
90.225
89.388
57.183
53.308
41.17
Repayment capacity
None
None
None
4.437
None
None
Cash flow / Revenue
None%
None%
None%
9.584%
None%
None%
Sector positioning
Debt ratio
126.612025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average+25 pts over 3 years
In 2025, the debt ratio of PHARMACIE BREVIERE (126.61) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
41.17%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average-26 pts over 3 years
In 2025, the financial autonomy of PHARMACIE BREVIERE (41.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
4.44 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Average
In 2023, the repayment capacity of PHARMACIE BREVIERE (4.44) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 624.02. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
624.019
Liquidity indicators evolution PHARMACIE BREVIERE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2020
2021
2022
2023
2024
2025
Liquidity ratio
1174.358
1167.794
904.654
1215.442
623.815
624.019
Interest coverage
None
None
None
0.081
None
None
Sector positioning
Liquidity ratio
624.022025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of PHARMACIE BREVIERE (624.02) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
0.08x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE BREVIERE (0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE BREVIERE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
1 236 150 €
0 €
0 €
Inventory turnover (days)
0
0
0
30
0
0
Customer payment term (days)
0
0
0
29
0
0
Supplier payment term (days)
0
0
0
24
0
0
Positioning of PHARMACIE BREVIERE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE BREVIERE is estimated at
4 923 687 €
(range 3 341 237€ - 7 725 944€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
3341k€4923k€7725k€
4 923 687 €Range: 3 341 237€ - 7 725 944€
NAF 5 année 2025
Valuation method used
Net Income Multiple
309 956 €
×
15.9x
=4 923 688 €
Range: 3 341 238€ - 7 725 944€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BREVIERE with other companies in the same sector:
Frequently asked questions about PHARMACIE BREVIERE
What is the revenue of PHARMACIE BREVIERE ?
The revenue of PHARMACIE BREVIERE in 2023 is 3.2 M€.
Is PHARMACIE BREVIERE profitable?
Yes, PHARMACIE BREVIERE generated a net profit of 310 k€ in 2025.
Where is the headquarters of PHARMACIE BREVIERE ?
The headquarters of PHARMACIE BREVIERE is located in CHASSENEUIL-SUR-BONNIEURE (16260), in the department Charente.
Where to find the tax return of PHARMACIE BREVIERE ?
The tax return of PHARMACIE BREVIERE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BREVIERE operate?
PHARMACIE BREVIERE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart